Aldeyra Therapeutics, Inc. Common Stock (ALDX) Stock
Key stats
- Market cap
- $39.32M
- Price / Earnings ratio
- -2.0x
- EPS (TTM)
- -$0.31
- Volume
- Loading
- 52-week high
- $5.93
- 52-week low
- $0.53
Source: third-party data provider, as of November 13, 2026
Compare with ALDX
Recent news

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
ALDX

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
ALDX

Aldeyra Therapeutics to Host Regulatory Update Webcast
Aldeyra Therapeutics to Host Regulatory Update Webcast
ALDX

Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
ALDX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 38.03
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.13
- MACD histogram
- 0.03
- SMA 50
- $1.00
- Price below SMA 50
- EMA 50
- $0.95
- Price below EMA 50
- SMA 200
- $2.10
- Price below SMA 200
- EMA 200
- $2.24
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
ALDX

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
ALDX

Aldeyra Therapeutics to Host Regulatory Update Webcast
Aldeyra Therapeutics to Host Regulatory Update Webcast
ALDX

Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
ALDX

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
ALDX

Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
ALDX

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALDX

ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
ALDX

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.
Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.
ALDX

ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
ALDX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Aldeyra Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Todd C. Brady M.D., Ph.D. | CEO, President & Director | 1972 |
| Mr. Michael Alfieri | Head of Finance and Principal Financial & Accounting Officer | 1965 |
| David Burke | Head of Investor Relations | — |
| Laura Nichols | Operations Manager | — |
| Dr. Adam Lazorchak | Director of Translational Sciences & Non-Clinical Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 38.03
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.13
- MACD histogram
- 0.03
- SMA 50
- $1.00
- Price below SMA 50
- EMA 50
- $0.95
- Price below EMA 50
- SMA 200
- $2.10
- Price below SMA 200
- EMA 200
- $2.24
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $2.00
- Average
- $5.50
- High
- $9.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.4 | -45.8 | ||||||||||
| 2022 | -14.1 | +8.6 | +14.1 | -34.8 | +1.3 | +35.7 | +32.6 | +38.3 | -25.3 | +3.6 | +0.5 | +13.0 |
| 2023 | -15.2 | +11.4 | +40.1 | -3.1 | -5.9 | -19.1 | +1.8 | -6.8 | -11.8 | -71.8 | +9.1 | +22.7 |
| 2024 | -11.6 | +13.5 | -22.5 | +20.5 | -8.1 | -13.8 | +21.2 | +55.3 | -6.9 | -0.6 | -8.6 | +3.5 |
| 2025 | +0.4 | -1.2 | -5.1 | -51.6 | -20.7 | +80.7 | +27.0 | +21.4 | -9.2 | -3.2 | +4.8 | -1.1 |
| 2026 | +14.8 | +0.6 | -69.9 | -9.5 | +10.1 | +28.3 | -36.6 | -3.3 | -17.4 | -56.6 | +12.1 |



